Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• Breast cancer is a leading cause of death in women globally.
• Herceptin is an effective but expensive targeted therapy for HER2-positive breast cancer, with limited survival benefits.
• The study addresses the need for more effective and potentially less costly breast cancer treatments.

Purpose of the Study:

• To develop a novel immunoconjugate by combining Herceptin with botulinum toxin.
• To enhance the therapeutic efficacy of Herceptin for HER2-positive breast cancer.
• To explore potential reductions in cost and adverse effects associated with Herceptin treatment.

Main Methods:

• Botulinum toxin was chemically conjugated to Herceptin using heterobifunctional crosslinkers (SATP and SMCC).
• The efficacy of the Herceptin-Toxin bioconjugate was evaluated on SK-BR-3 and BT-474 breast cancer cell lines.
• Cytotoxicity was assessed using the Alamar blue assay and a fluorescence plate reader.

Main Results:

• The Herceptin-Toxin bioconjugate demonstrated significantly improved efficacy compared to Herceptin alone.
• Enhanced therapeutic effect was observed in both tested breast cancer cell lines (SK-BR-3 and BT-474).

Conclusions:

• Toxin-Herceptin bioconjugation represents a promising strategy for enhancing breast cancer treatment.
• This approach offers potential for increased efficiency in managing HER2-receptor-overexpressing breast cancers.
• Further investigation may lead to improved therapeutic options for breast cancer patients.